$XBI $125.63 -1.7%
Covid Updates
$VBIV -4.3% VBI Vaccines Announces New Preclinical Data and Initiation of VBI-2905 Clinical Study Targeting Broadened Immunity Against COVID-19 and Variants of Concern. source
$NRXP -1.5% NRx Pharmaceuticals Announces Second Favorable Safety Report for ZYESAMI™ (aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19. source
$ADGI +2.6% Adagio Therapeutics Announces New Data Highlighting the Potential of ADG20 for Treatment and Prevention of COVID-19. source
Pipeline Updates
$MIRM -0.4% U.S. FDA APPROVES LIVMARLI (MARALIXIBAT) AS THE FIRST AND ONLY APPROVED MEDICATION FOR THE TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS WITH ALAGILLE SYNDROME ONE YEAR OF AGE AND OLDER source
$LGVN -4.8% Longeveron Announces Potential Biomarker Correlating with Lomecel-B Bioactivity source
$DNLI -2.2% Denali Therapeutics Announces Upcoming Presentations on EIF2B Activator DNL343 and RIPK1 Inhibitor SAR443820/DNL788 at the 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting source
$EDIT -19.0% Editas Medicine Announces Positive Initial Clinical Data From Ongoing Phase 1/2 BRILLIANCE Clinical Trial Of EDIT-101 For LCA10 source
$HEPA -0.7% All Endpoints Met in Hepion Pharmaceuticals’ Drug-Drug Interaction Study with CRV431 source
$WVE -9.4% Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a Clinical Trial of WVE-N531 in Duchenne Muscular Dystrophy source
$SCYX -2.6% SCYNEXIS Presents Interim Analysis from FURI at Virtual IDWeek 2021 Showing Favorable Therapeutic Response in Severe Hospital-Based Fungal Infections Treated with Oral Ibrexafungerp source
$ATHA +- 0.0% Athira Pharma to Present Updates from Phase 2/3 Trials of ATH-1017 at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference source
$KRYS -2.5% Krystal Biotech Receives Approval from the Human Research Ethics Committee in Australia for Phase 1 Trial of KB407 for Cystic Fibrosis source
$SYRS -4.4% Syros Announces First Patient in Dose Confirmation Study of SY-2101, a Novel Oral Form of Arsenic Trioxide, in Acute Promyelocytic Leukemia source
$NCNA +17.3% NuCana Receives Fast Track Designation from the U.S. Food and Drug Administration for Acelarin® (NUC-1031) for the Treatment of Biliary Tract Cancer source
$HGEN -0.5% Humanigen Announces Oral Presentation of Lenzilumab LIVE-AIR Phase 3 Study Results at IDWeek 2021 source
$ADCT -4.1% Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Pivotal Phase 2 Clinical Trial for Diffuse Large B-cell Lymphoma source
$TGTX +1.6% TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. source
$KLDO +1.5% Kaleido Biosciences to Host Virtual R&D Presentation to Discuss Clinical Data and Pipeline Advancement on October 5, 2021. source
$CFRX -4.0% ContraFect to Present New Late Breaking Phase 2 Exebacase Data on Rapid Symptom Resolution Among Patients with Staphylococcus aureus Bacteremia at IDWeek™ 2021. source
$TMDX +4.6% TransMedics Receives FDA Approval for its OCS Liver System for Preservation and Assessment of Donor Livers for Transplantation. source
$HZNP +2.5% Horizon Therapeutics plc Announces New Development Programs at Virtual R&D Day . source
$SLDB -2.9% Solid Biosciences Reports Additional Pulmonary Function Results from the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001. source
$TSHA -4.2% Taysha Gene Therapies Receives Orphan Drug Designation from the European Commission for TSHA-101 for the Treatment of Infantile GM2 Gangliosidosis. source
$FOLD -5.1% U.S. FDA Accepts Filings for Amicus’ AT-GAA for the Treatment of Pompe Disease. source
$CLDX -2.6% Celldex Presents Positive Data on Symptom Control and Quality of Life Measurements that Further Support CDX-0159 Clinical Benefit in Phase 1b Study in Chronic Inducible Urticaria at EADV 2021. source
$HCM -0.4% HUTCHMED Highlights Oral Presentations at 2021 Chinese Society of Clinical Oncology Annual Meeting. source
Financial & Business Updates
$MNKD -2.8% Mannkind Corporation Announces Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds source
$ASND -1.7% Ascendis Pharma A/S Announces Share Repurchase Program source
$FBIO +5.9% Fortress Biotech Announces Receipt of Notice of Option Exercise from AstraZeneca to Fully Acquire Caelum Biosciences, a Company Founded by Fortress Biotech. source
$FOLD -5.1% Amicus Therapeutics and ARYA Sciences Acquisition Corp IV Announce Formation of a Next-Generation Genetic Medicine Company: “Caritas Therapeutics”. source
Posted by FS/JM
Comments